Nifty Pharma index rises 2% as Sun Pharma, Lupin receive USFDA approval

Sun Pharma rose over 3 per cent to an intra-day high of Rs 670.90 on the NSE after the drug maker announced USFDA approval of XELPROS to treat open-angle Glaucoma or Ocular Hypertension.

from Latest News https://ift.tt/2MwjmsS
https://ift.tt/eA8V8J https://ift.tt/2LUVdkd

• Tweet
• Share
• Share
• Share
• Share